Astellas Study Results Available for ASP0367 (MA-0211) in Pediatric Male Patients with Duchenne Muscular Dystrophy

November 16, 2023

On November 15, 2023, Astellas Pharma shared a community letter with information on obtaining results for ASP0367 (MA-0211) in Pediatric Male patients with Duchenne muscular dystrophy.

Astellas’ Community Letter can be found by clicking here.

Astellas’ clinical trial study details can be found on their website.

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open